A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer.
Saved in:
| Title: | A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. |
|---|---|
| Authors: | Yang, Lu1 (AUTHOR), Bhattacharya, Arup1 (AUTHOR), Li, Yun1 (AUTHOR), Peterson, Darrell2 (AUTHOR), Zhang, Yuesheng1,2,3 (AUTHOR) yuesheng.zhang@vcuhealth.org |
| Source: | Scientific Reports. 4/20/2026, Vol. 16 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20452322 |
|---|---|
| DOI: | 10.1038/s41598-026-47444-3 |
